Join the Bimekizumab group to help and get support from people like you.
Bimekizumab News
Review Compares Efficacy, Safety of Treatments for Hidradenitis Suppurativa
MONDAY, July 7, 2025 – The efficacy and safety of currently approved and pipeline medications for moderate-to-severe hidradenitis suppurativa (HS) are compared in a systematic literature review and...
UCB Receives U.S. FDA Approval for Bimzelx (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate to Severe Hidradenitis Suppurativa
Brussels (Belgium), November 20, 2024 – 07:00 (CET) – UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Bimzelx® (bimek...
Monthly News Roundup - October 2024
FDA Approves AbbVie’s Vyalev to Treat Advanced Parkinson Disease In October, the US Food and Drug Administration (FDA) approved Vyalev (foscarbidopa and foslevodopa) for the treatment of motor f...
UCB Receives U.S. FDA Approval for 320 mg Single-Injection Device Presentations of Bimzelx (bimekizumab-bkzx)
Brussels (Belgium), October 14, 2024 – 07:00 (CEST) – UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved a 2 mL pre-filled syringe a...
Bimekizumab Safe, Efficacious Over Two Years for Hidradenitis Suppurativa
MONDAY, Oct. 7, 2024 – For patients with hidradenitis suppurativa (HS), bimekizumab is safe and efficacious over two years, according to a study presented at the annual meeting of the European...
UCB announces U.S. FDA approvals for Bimzelx (bimekizumab-bkzx) for the treatment of psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis
Brussels (Belgium), September 23, 2024 – 07:00 (CEST) – UCB, a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved Bimzelx (bi...
FDA Approves Bimzelx (bimekizumab-bkzx) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis
Brussels (Belgium), 18 OCTOBER 2023 – UCB, a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved Bimzelx® (bimekizumab-bkzx) for the tr...
Further information
Related condition support groups
Hidradenitis Suppurativa, Ankylosing Spondylitis, Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, Plaque Psoriasis